Subscribe to RSS
DOI: 10.1055/s-0030-1263310
© Georg Thieme Verlag KG Stuttgart · New York
Psoriasis als unabhängiger Risikofaktor für die Entwicklung einer koronaren Herzkrankheit
Psoriasis as an independent risk factor for development of coronary artery diseasePublication History
eingereicht: 2.3.2010
akzeptiert: 10.6.2010
Publication Date:
01 September 2010 (online)

Zusammenfassung
Psoriasis ist eine chronisch-entzündliche Dermatose mit schubweisem Verlauf. Die bekannteste Komorbidität stellt die Psoriasisarthritis dar. Im klinischen Alltag fällt auf, dass Psoriasispatienten häufiger klassische kardiovaskuläre Risikofaktoren wie Adipositas, Diabetes mellitus, Hyperliproteinämie, arterielle Hypertonie, Nikotinabusus bis hin zum Metabolischen Syndrom aufweisen und häufiger an koronarer Herzerkrankung leiden als Nichtpsoriatiker. Dies konnte durch zahlreiche klinische und epidemiologische Studien belegt werden. In den letzten Jahren kristallisiert sich zunehmend die Rolle der Psoriasis als eigenständiger kardiovaskulärer Risikofaktor heraus, unabhängig von begleitenden klassischen Risikofaktoren. Dieser Artikel fasst den bisherigen Stand der Kenntnisse zur Komorbidität zwischen Psoriasis und koronarer Herzerkrankung zusammen und diskutiert mögliche gemeinsame immunpathologische Mechanismen.
Abstract
Psoriasis is a chronic inflammtory dermatosis with a relapsing course. The best known comorbidity is psoriatic arthritis. In daily clinical practise it is well known, that patients with psoriasis show more often classic cardiovaskular risk factors such as obesity, Diabetes mellitus, hyperlipoproteinemia, hypertension, nicotine abuse often presenting as Metabolic Syndrome and suffer more often from coronary heart disease than patients without psoriasis. This could be demonstraded in numerous clinical and epidemiologic studies. In the last few years there is increasing evidence for psoriasis beeing an independent cardiovascular risk factor despite of concomitant classic risk factors. This review summarizes the current state of research and discusses possible common immunpathogenetic mechanisms.
Schlüsselwörter
Psoriasis - koronare Herzkrankheit - Myokardinfarkt - Risikofaktoren - Entzündung
Keywords
Psoriasis - coronary artery disease - myocardial infarction - risk factors - inflammation
Literatur
- 1
Aicher A, Heeschen C, Mohaupt M. et al .
Nicotine strongly activates dentritic cell-mediated
adaptive immunitiy: potential role for progression of atherosclerotic
lesions.
Circulation.
2003;
107
604-611
MissingFormLabel
- 2
Alberti K G, Zimmet P Z.
Definition,
diagnosis of diabetes mellitus and its complications, I: diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation.
Diabet Med.
1998;
15
539-553
MissingFormLabel
- 3
Alexandroff A B, Pariah Camp R DR, Lang C C, Struthers A D, Armstrong D J.
More than skin deep: atherosclerosis
as a systemic manifesation of psoriasis.
Br J Dermatol.
2009;
161
1-7
MissingFormLabel
- 4
Boehncke W H, Buerger C, Boehncke S.
Komorbiditäten bei Psoriasis vulgaris.
Hautarzt.
2009;
60
116-121
MissingFormLabel
- 5
Boehncke S, Thaci D, Beschmann H. et al .
Psoriasis patients show signs of insulin
resistance.
Br J Dermatol.
2007;
157
1249-1251
MissingFormLabel
- 6
Choi K H, Hernan M A, Seeger J D. et al .
Methotrexate and mortality
in patients with rheumatoid arthritis: a prospective study.
Lancet.
2002;
359
1173-1177
MissingFormLabel
- 7
Christophers E.
Psoriasis – epidemiology and clinical spectrum.
Clin
Exp Dermatol.
2001;
26
314-320
MissingFormLabel
- 8 Schwandt P, Richter W O. Adipostas. In: Classen M, Diehl V, Kochsiek K, Innere Medizin.
4. Auflage. Urban und Schwarzenberg; 1998: 787
MissingFormLabel
- 9
Dixon W G, Watson K D, Lunt M. et al .
Reduction oin the incidence of myokardial
infarction in patients with rheumatoid arthritis who respond to
anti-tumor necrosis factor alpha therapy: results from the British
Society for Rheumatology Biologics Register.
Arthritis
Rheum.
2007;
56
2905-2912
MissingFormLabel
- 10
Executive Summary of The Third
Report of The National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation and Treatment of High Blood Cholesterol
in Adults (Adult Panel III).
JAMA.
1998;
285
2486-2497
MissingFormLabel
- 11
Friedewald V E, Cather C C, Gelfand J M. et al .
AJC Editor’s Consensus:
Psoriasis and Coronary Artery Disease.
Am J Cardiol.
2008;
102
1631-1643
MissingFormLabel
- 12 Fritsch P. Erythematosquamöse Dermatosen. In: Fritsch
P, Dermatologie Venerologie. 2. Auflage. Berlin
Heidelberg New York: Springer-Verlag; 2004: 360-374
MissingFormLabel
- 13
Gelfand J M, Weinstein R, Porter S B. et al .
Prevalence and treatment of psoriasis in
the United Kingdom: a population based study.
Arch Dermatol.
2005;
141
11537-11541
MissingFormLabel
- 14
Gelfand J M, Neimann A L, Shin D B. et al .
Risk of myocardial infarction in
patients with psoriasis.
JAMA.
2006;
296
1735-1741
MissingFormLabel
- 15
Gelfand J M, Troxel A B, Lewis J D. et al .
The risk of mortality in
patients with psoriasis: results from a population-based study.
Arch Dermatol.
2007;
143
1493-1499
MissingFormLabel
- 16
Gisondi P, Tessari G, Conti A, Piaserico S, Peserico A, Gianetti A, Girolomoni G.
Prevalence of metabolic syndrome in patients with psoriasis:
a hospital-besed case-control study.
Br J Dermatol.
2007;
157
68-73
MissingFormLabel
- 17
Hansson G K.
Inflammation, Atherosclerosis and Coronary Artery Disease.
N Engl J Med.
2005;
352
1685-1695
MissingFormLabel
- 18
Henseler T, Christophers E.
Disease concomitance
in psoriasis.
J Am Acad Dermatol.
1995;
32
982-986
MissingFormLabel
- 19
Herron M D, Hinckley M, Hofman M S. et al .
Impact of obesity and smoking om psoriasis
presentation and management.
Arch Dermatol.
2005;
141
1527-1534
MissingFormLabel
- 20
Jacobsson L T, Turesson C, Gülfe A. et al .
Treatment with tunor necrosis factor blockers
is associated with a lower incidence of first cardiovascular events im
patients with rheumatoid arthritis.
J Rheumatol.
2005;
32
1213-1218
MissingFormLabel
- 21
Katz H I, Waalen J, Leach E E.
Acitretin in psoriasis: an overview of adverse effects.
J
Am Acad Dermatol.
1999;
41
S7-S12
MissingFormLabel
- 22
Kremers H M, Crowson C S, Nicola P J, Ballmann K V. et
al .
Increased unrecognized coronary heart disease and
sudden deaths in rheumatoid arthritis: a population-based cohort
study.
Arthritis Rheum.
2005;
52
402-411
MissingFormLabel
- 23
Kremers H M, Mc Evoy M T, Dann F. et al .
Heart disease in psoriasis.
J
Am Acad Dermatol.
2007;
57
347-354
MissingFormLabel
- 24
Kwak B, Mulhaupt F, Myit S, Mach F.
Statins as a mewly recognized
type of immunomodulator.
Nat Med.
2000;
6
1399-1402
MissingFormLabel
- 25
Lakka H M, Laaksonen D E, Lakka T A. et al .
The metabolic syndrome and
cardiovascular disease mortality in middle-aged man.
JAMA.
2002;
288
2709-2716
MissingFormLabel
- 26
Lindegard B.
Diseases associated withpsoriasis in a generl population of 159.200
middle-aged, urban, native Swedes.
Dermatologica.
1986;
172
298-304
MissingFormLabel
- 27
Ludwig R J, Herzog C, Rostock A, Ochsendorf F R, Zollner T M, Thaci D, Vogl T J, Boehncke W H.
Psoriasis: a possible risk factor for development of coronary artery
calcification.
Br J Dermatol.
2006;
156
271-276
MissingFormLabel
- 28
Mallbirs L, Akre O, Granath F. et al .
Increased risk for cardiovaskular mortality
in psoriasis inpatients but not in outpatients.
Eur J
Epidemiol.
2004;
19
225-230
MissingFormLabel
- 29
Mallbris L, Granath F, Hamsten A, Stahle M.
Psoriasis is associated
with lipid abnormalities at the onset of skin disease.
J
Am Acad Dermatol.
2006;
54
614-621
MissingFormLabel
- 30
Mann D L, McMurray J JV, Packer M, Swedberg K. et al .
Targeted
anticytokine therapy in patients with chronic heart failure: Results
of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Circulation.
2004;
109
1594-1602
MissingFormLabel
- 31
McCarey D W, McInnes I B, Mashok R. et al .
Trial of Atorvastatin in Rheumatoid Arthritis
(TARA): double-blind, randomised Placebo-controlled trial.
Lancet.
2004;
363
2015-2021
MissingFormLabel
- 32
McDonald C J, Calabresi P.
Complication of Psoriasis.
JAMA.
1973;
224
629
MissingFormLabel
- 33
McDonald C J, Calabresi P.
Occlusive vascular
disease in psoriatic patients.
N Engl J Med.
1973;
288
912
MissingFormLabel
- 34
Mehta N N, Azfar R S, Shin D B, Neimann A L, Troxel A B, Gelfand J M.
Patients with severe psoriasis are at increased risk of cardiovascular
mortality: cohort study using the General Practice Research Database.
Eur Heart J.
2010;
31
1000-1006
MissingFormLabel
- 35
Naldi L.
Cigarette smoking and psoriasis.
Clin Dermatol.
1998;
16
571-574
MissingFormLabel
- 36
Naldi L, Chatenoud L, Linder D. et al .
Cigarette smoking, body mass index and
stressfull life events as risk factors for psoriasis: results from
an Italian case control study.
J Invest Dermatol.
2005;
125
61-67
MissingFormLabel
- 37
Neimann A L, Shin D B, Xingmei W, Margolis D J, Troxel A B, Gelfland J M.
Prevalence
of cardiovascular risk factors in patients with psoriasis.
J
Am Acad Dermatol.
2006;
55
829-835
MissingFormLabel
- 38
Neimann A L, Porter S B, Gelfand J M.
Epidemiology of psoriasis.
Expert
Rev Dermatol.
2006;
1
63-75
MissingFormLabel
- 39
Prodanovich S, Ma F, Taylor J R. et al .
Methotrexate reduces incidence of vascular
diseases in veterans with psoriasis or rheumatoid arthritis.
J
Am Acad Dermatol.
2005;
52
262-267
MissingFormLabel
- 40
Ridker P M.
Testing the inflammatory hypothesis of atherothrombosis: scientific
rationle for the cardiovascular inflammation reduction trial (CIRT).
J Throm Haemost.
2009;
7
(Suppl. 1)
332-339
MissingFormLabel
- 41
Ridker P M, Danielson E, Fonesca F HA. et al .
Reduction in C-reactive protein and LDL
cholesterol and cardiovacular event rates after initiation of rosuvastatin:
a prospective study oft he JUPITER trial.
Lancet.
2009;
373
1175-1182
MissingFormLabel
- 42
Rocha-Pereira P, Santos-Silva A, Rebelo I. et al .
Dislipidemia and oxidative stress in mild
and severe psoriasis as a risk for cardiovascular disease.
Clin Chim
Acta.
2001;
303
33-39
MissingFormLabel
- 43
Schoen T, Boehncke H W.
Psoriasis.
N Engl J Med.
2005;
352
1899-1912
MissingFormLabel
- 44
Setty A R, Curhan G, Choi H K.
Obesity, waist circumference, weight change and the risk of
psoriasis in women: Nurses Health Study II.
Arch Intern Med.
2007;
167
1670-1675
MissingFormLabel
- 45
Sommer D M, Jenisch S, Suchan M, Christophers E, Weichenthal M.
Increased prevalence of the metabolic syndrome in patients with
moderate to severe psoriasis.
Arch Dermatol Res.
2006;
298
321-328
MissingFormLabel
- 46
Sopori M.
Effects of cigarette smoke on the immune system.
Nat
Rev Immunol.
2002;
2
372-377
MissingFormLabel
- 47
Stern R S, Fitzgerald E, Ellis C N. et al .
The saftey of etretinate as long-term therapy
for psoriasis: results of the etretinate follow-up study.
J
Am Acad Dermatol.
1995;
33
44-52
MissingFormLabel
- 48
Taler S j, Textor C S, Canzanello V J, Schwartz L.
Cyclosporin-induced
hypertension: incidence, pathogenesis and management.
Drug
Saf.
1999;
20
437-449
MissingFormLabel
- 49
Wakkee M, Thio H B, Prens E P, Sijbrands E JG, Neumann H AM.
Unfavorable cardiovascular risk
profiles in untreated and treated psoriasis patients.
Atheroslerosis.
2007;
190
1-9
MissingFormLabel
- 50
Xiao J, Chen L H, TU Y T, Deng X H, Tao J.
Prevalence of myocardial infarction in patients with psoriasis
in central China.
JEADV.
2009;
23
1311-1315
MissingFormLabel
Dr. med. David Papo
Metzstr. 14
81667 München
Phone: 089/4140-3227
Email: davidpapo@58beats.com